Latest news - Novo Nordisk
WEBAug 6, 2024 · Latest news. 20 September 2024. Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed. Read more. 19 September 2024. Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function. Read more. 06 …
Company announcements and press releases - Novo Nordisk
WEBNovo Nordisk press releases and company announcements.
Novo Nordisk Wegovy approved for cutting heart disease risks
WEBMar 8, 2024 · That decision could widen insurance coverage for the drug and similar treatments for obesity, which has been a major barrier to access for patients.
Novo Nordisk to build $4.1 billion North Carolina facility to boost ...
WEBThe new plant in Clayton, North Carolina, will be responsible for filling and packaging syringes and injection pens for Wegovy, Ozempic and other drugs.
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy …
WEBApr 20, 2024 · Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
Novo Nordisk expects double-digit growth as it boosts Wegovy …
WEBCOPENHAGEN/LONDON, Jan 31 (Reuters) - Novo Nordisk on Wednesday forecast another year of double-digit growth as the Danish drugmaker began boosting U.S. supplies of its popular weight-loss drug...
News & media - Novo Nordisk
WEBGet an overview of the Novo Nordisk press releases here or subscribe to our news and get it directly in your mailbox when we have news to tell.
Novo Nordisk's Ozempic cuts risk of kidney disease progression
WEBMar 5, 2024 · The results add to the growing evidence that the highly popular injection has broader health benefits for patients beyond treating Type 2 diabetes.
News details - Novo Nordisk
WEBMar 8, 2024 · Novo Nordisk's commitment to the obesity and cardiovascular community is a long-term one, and we are investing significantly to build capacity to meet increasing demand. Please visit WegovySupply.com for the latest information.
Novo Nordisk signs deals worth up to $1bn with US biotechs in …
WEBJan 4, 2024 · Novo Nordisk has signed deals worth up to $1bn with US biotech start-ups developing treatments for obesity and other cardiometabolic diseases, as the Wegovy manufacturer seeks to stay ahead in...
- Some results have been removed